Butyrate impairs energy metabolism in isolated perfused liver of fed rats.
This study was designed to test the effects of short-chain fatty acids (SCFA) with an even number of carbon atoms on hepatic energy metabolism. The effect of the SCFA was evaluated by measuring liver ATP content and oxygen consumption. The ATP content was evaluated using (31)P nuclear magnetic resonance in isolated liver from fed rats. In addition, respiratory activity (VO(2)) was assessed using Clark electrodes. The livers were perfused with acetate, butyrate or a medium chain length fatty acid, octanoate, at a concentration of 0.05--5.0 mmol/L. The addition of each substrate enhanced the rate of the net ATP consumption (V(i)), establishing a new ATP steady state that required a perfusion time of > or = 20 min, dependent on the chain length and concentration of the fatty acid (FA). The initial V(i) was unchanged for acetate and the ATP level stabilized at 58% of the initial level. Both butyrate and octanoate induced a dose-dependent increase in V(i). This may reflect an ATP-consuming process for the intracellular pH regulation observed during the acidosis associated with the beta-oxidation pathway. At the new steady state, the ATP concentration was approximately 45% of the initial level for both FA. VO(2) was both rapidly and reversibly increased, and the change was a function of butyrate or octanoate concentration and of the chain length. K(m) values were similar for butyrate and octanoate. Because all of the effects were similar for butyrate and octanoate, in contrast to acetate, we suggest that the impairment of the energy metabolism by butyrate resulted from an increase in the FADH(2)/NADH ratio due to beta-oxidation. In conclusion, the difference in the hepatic oxidation pathways of two products of intestinal fermentation (acetate and butyrate) explains their different actions on energy metabolism.
Beauvieux
M C
MC
Service de Nutrition et Diabétologie, Hôpital Haut-Lévêque, F-33600 Pessac France. mcdb@rmsb.u-bordeaux2.fr
Tissier
P
P
Gin
H
H
Canioni
P
P
Gallis
J L
JL
D000085:Acetates / Q000493:pharmacokinetics / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D002087:Butyrates / Q000493:pharmacokinetics / Q000494:pharmacology*; D002210:Caprylates / Q000493:pharmacokinetics / Q000494:pharmacology; D002478:Cells, Cultured; D004734:Energy Metabolism / Q000187:drug effects*; D005232:Fatty Acids, Volatile / Q000493:pharmacokinetics / Q000494:pharmacology; D006863:Hydrogen-Ion Concentration; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D010084:Oxidation-Reduction; D010101:Oxygen Consumption; D010477:Perfusion / Q000662:veterinary; D010759:Phosphorus Isotopes; D051381:Rats; D017208:Rats, Wistar
D000085:Acetates; D002087:Butyrates; D002210:Caprylates; D005232:Fatty Acids, Volatile; D010759:Phosphorus Isotopes; D000255:Adenosine Triphosphate; C031492:octanoic acid